ARTICLE | Product Development

COVID R&D consortium launches I-SPY adaptive trial with Quantum Leap

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 29, 2020 4:00 AM UTC
Updated on Apr 29, 2020 at 2:47 PM UTC

The COVID R&D consortium is making good on its intention to push forward experimental therapies as fast as possible, partnering with Quantum Health to launch an I-SPY adaptive trial to evaluate 10-20 agents within a year to treat ARDS, the late-stage respiratory failure that can lead to death in COVID-19. The trial is the first output of the COVID R&D group unveiled by BioCentury this month.

COVID R&D, a precompetitive industry consortium comprising more than a dozen of the top pharma companies, has prioritized the use of master protocols as an efficient way to study multiple candidates in parallel. It is evaluating compounds from the member pharmas’ own pipelines as well as from other investigators or companies, agnostic to market potential (see “Pharmas Align Behind Crowdsourcing Solution”)...